Evidence map›Paper›PMID 38026958›Full record

ArticleFrontiers in pharmacology2023

Efficacy and safety of high-dose ilaprazole-amoxicillin dual therapy for

Jianping Cheng, Chanjuan Fan, Kun Huang, Lili Zhai, Hui Wang, Dongling Xie, Yong Cai, Zhen Li, Qixuan Bai, Pan Wang and 1 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Amoxicillin high-dose dual therapy forWorld journal of gastroenterology · 2025
    Trial
  5. Trial
  6. Antibiotics (Basel, Switzerland) · 2026
    Review
  7. Real-World Situation of Eradication Regimens and Risk Factors forClinical and experimental gastroenterology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jianping ChengDepartment of Gastroenterology and Oncology, Civil Aviation General Hospital, Beijing, China.
Chanjuan FanDepartment of Gastroenterology and Oncology, Civil Aviation General Hospital, Beijing, China.
Kun HuangDepartment of Gastroenterology and Oncology, Civil Aviation General Hospital, Beijing, China.
Lili ZhaiDepartment of Gastroenterology and Oncology, Civil Aviation General Hospital, Beijing, China.
Hui WangDepartment of Gastroenterology and Oncology, Civil Aviation General Hospital, Beijing, China.
Dongling XieDepartment of Gastroenterology and Oncology, Civil Aviation General Hospital, Beijing, China.
Yong CaiDepartment of Gastroenterology and Oncology, Civil Aviation General Hospital, Beijing, China.
Zhen LiDepartment of Gastroenterology and Oncology, Civil Aviation General Hospital, Beijing, China.
Qixuan BaiDepartment of Gastroenterology and Oncology, Civil Aviation General Hospital, Beijing, China.
Pan WangDepartment of Gastroenterology and Oncology, Civil Aviation General Hospital, Beijing, China.
Haiou DingDepartment of Gastroenterology and Oncology, Civil Aviation General Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

dual therapyeradicationHelicobacter pyloriilaprazoleproton‐pump inhibitor

Identifiers

PMID38026958
PMCPMC10661892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.